Akanksha Jain’s Post

View profile for Akanksha Jain, graphic

RQAP-GCP QA | Compliance & Auditing Expert | Freelance | Auditor| Trainer| Consultant

🚀 𝐋𝐚𝐮𝐧𝐜𝐡𝐢𝐧𝐠 𝐌𝐲𝐭𝐡 𝐕𝐬 𝐅𝐚𝐜𝐭 𝐒𝐞𝐫𝐢𝐞𝐬 There are so many myths surrounding Clinical Trials, their processes, and even some of the roles within the industry! These misconceptions can create confusion and mislead people, which is why I’m launching a special series called "𝐌𝐲𝐭𝐡𝐬 𝐯𝐬 𝐅𝐚𝐜𝐭𝐬" to share some of the most common myths vs the fact. For the next 𝐭𝐰𝐨 𝐰𝐞𝐞𝐤𝐬, I’ll be sharing insights on various myths that are often believed to be true in the world of clinical research—whether it’s about trial designs, monitoring, or the responsibilities of clinical roles. 𝐇𝐞𝐫𝐞 𝐢𝐬 𝐭𝐡𝐞 𝐟𝐢𝐫𝐬𝐭 𝐩𝐨𝐬𝐭 𝐟𝐫𝐨𝐦 𝐭𝐡𝐞 𝐬𝐞𝐫𝐢𝐞𝐬! 💡  𝐑𝐢𝐬𝐤-𝐁𝐚𝐬𝐞𝐝 𝐌𝐨𝐧𝐢𝐭𝐨𝐫𝐢𝐧𝐠 (𝐑𝐁𝐌) has been a significant shift in the world of clinical trials over the past few years, moving away from traditional on-site monitoring to a more data-driven and targeted approach. RBM focuses on identifying, assessing, and mitigating risks throughout the clinical trial process, allowing sponsors to prioritize critical data points and sites for oversight. As the industry recognized its efficiency and effectiveness, RBM gained immense visibility and adoption across trials globally. However, with this growing adoption, misconceptions and myths have also emerged, often due to a lack of understanding or experience with this model. 𝐇𝐞𝐫𝐞 𝐚𝐫𝐞 𝐭𝐡𝐞 𝐭𝐨𝐩 𝐓𝐇𝐑𝐄𝐄 𝐦𝐲𝐭𝐡𝐬 I've encountered during conversations with professionals. 𝐈’𝐝 𝐥𝐨𝐯𝐞 𝐭𝐨 𝐡𝐞𝐚𝐫 𝐲𝐨𝐮𝐫 𝐭𝐡𝐨𝐮𝐠𝐡𝐭𝐬 𝐚𝐧𝐝 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞𝐬—𝐬𝐡𝐚𝐫𝐞 𝐲𝐨𝐮𝐫 𝐢𝐧𝐬𝐢𝐠𝐡𝐭𝐬, 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞𝐬, 𝐨𝐫 𝐛𝐮𝐬𝐭 𝐬𝐨𝐦𝐞 𝐦𝐲𝐭𝐡𝐬 𝐲𝐨𝐮𝐫𝐬𝐞𝐥𝐟! #clinicalresearch #qualitymanagementsystem #goodclinicalpractices #ICHGCP #Riskbasedmonitoring #RBM #remote #MythsVsFacts #GCP #ClinicalTrials #Monitoring #ClinicalDesign #remoteMonitoring #GlobalClinicalTrials #Quality #QualityAssurance

To view or add a comment, sign in

Explore topics